
Intravenous iron treatment does not increase infection risks in heart failure. In the IRONMAN trial, IV ferric derisomaltose (FDI) in patients with heart failure and iron deficiency showed a trend toward reduced hospitalizations due to infection (HR 0.76, p=0.032). There was no significant increase in infection-related death or hospitalization with FDI. The infection reduction was primarily seen in patients with TSAT <20%. These findings suggest a beneficial role of iron therapy without compromising safety.
Like
Save
Share